Skip to Content
How to talk to a doctor about advanced ovarian cancer >>

Idarubicin Pregnancy and Breastfeeding Warnings

Idarubicin is also known as: Idamycin, Idamycin PFS

Idarubicin Pregnancy Warnings

AU: Contraindicated UK, US: This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. AU TGA pregnancy category: D US FDA pregnancy category: D Comments: -This drug can harm a developing fetus. -Women of childbearing potential should be advised not to become pregnant during treatment and to use adequate contraception during therapy. -This drug can induce chromosomal damage in human spermatozoa; therefore, males undergoing therapy should use effective contraceptive methods for up to 3 months after completing treatment. -Women of childbearing potential should be informed of the potential hazard to the fetus. -Women attempting to have children after completion of therapy should be advised to obtain genetic counseling first, if appropriate.

A single case in which idarubicin was given during pregnancy has been reported. Data are available for other anthracyclines. A 26-year-old woman presented at 20 weeks' gestation with acute myelogenous leukaemia (AML) received daunorubicin and cytarabine as induction therapy, but required retreatment after 3 weeks due to unequivocal evidence of persistence of acute leukaemia. She received mitoxantrone (mitozantrone) and cytarabine as her second course of chemotherapy. Complete remission and a normal foetal growth rate were documented after a total of 60 days from the start of therapy. Due to the long period of time required to obtain remission, it was decided to consolidate therapy with idarubicin 10 mg/m2 (with cytarabine) at approximately 32 weeks' gestation. She tolerated the treatment well and was discharged only to return two days later complaining of abdominal pain and lack of foetal activity for six to eight hours. After ultrasonographic evidence of foetal death, labour was induced, and the patient delivered a stillborn foetus with no obvious congenital malformations weighing 2,200 grams. Autopsy permission was denied. Limited data have shown that it is possible to give a single very high dose cycle of chemotherapy for AML in younger women without compromising fertility.

See references

Idarubicin Breastfeeding Warnings

UK: Contraindicated AU, US: Use is not recommended Excreted into human milk: Unknown Excreted into animal milk: Data not available Comment: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):

References for breastfeeding information

  1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide